Year All2026202520242023 Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights May 15, 2024 Read more Aileron Therapeutics to Present at Two Upcoming Investor Conferences May 6, 2024 Read more Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million May 3, 2024 Read more Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million May 1, 2024 Read more Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) May 1, 2024 Read more Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update April 15, 2024 Read more Aileron Therapeutics Announces CEO Transition March 12, 2024 Read more Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event February 15, 2024 Read more Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024 February 1, 2024 Read more Aileron Therapeutics Announces Acquisition of Lung Therapeutics October 31, 2023 Read more
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights May 15, 2024 Read more
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million May 3, 2024 Read more
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million May 1, 2024 Read more
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) May 1, 2024 Read more
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update April 15, 2024 Read more
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event February 15, 2024 Read more
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024 February 1, 2024 Read more
